Best practice guidelines promote generic (non-proprietary) prescribing. In New Zealand the generic name is the International Non-proprietary Name (INN).
However, there are some circumstances where it is preferable to prescribe by brand (trade) name. For example, where different brands of the same chemical have specific formulation release characteristics, or where products have multiple ingredients: situations that can result in therapeutic non-equivalence or confusion.
Specify brand advice (SBA) status is applied within the New Zealand Medicines Terminology dataset to medicines when, in the interests of patient safety, practicality, and avoidance of confusion, the brand of the medicine should be used in addition to the generic name. The SBA status is assigned by the New Zealand Universal List of Medicines (NZULM) editorial team.